Skip to main content
NASDAQ:GNCA

Genocea Biosciences Competitors

$2.19
+0.13 (+6.31 %)
(As of 05/14/2021 01:31 PM ET)
Add
Compare
Today's Range
$2.10
$2.23
50-Day Range
$2.10
$2.82
52-Week Range
$1.74
$5.75
Volume4,099 shs
Average Volume500,497 shs
Market Capitalization$119.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33

Competitors

Genocea Biosciences (NASDAQ:GNCA) Vs. OYST, APTO, GRTS, JNCE, CDAK, and AVRO

Should you be buying GNCA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Genocea Biosciences, including Oyster Point Pharma (OYST), Aptose Biosciences (APTO), Gritstone bio (GRTS), Jounce Therapeutics (JNCE), Codiak BioSciences (CDAK), and AVROBIO (AVRO).

Genocea Biosciences (NASDAQ:GNCA) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Genocea Biosciences and Oyster Point Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-1.64

Oyster Point Pharma is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Oyster Point Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
Oyster Point Pharma00103.00

Genocea Biosciences currently has a consensus price target of $7.25, indicating a potential upside of 231.05%. Given Genocea Biosciences' higher probable upside, equities analysts plainly believe Genocea Biosciences is more favorable than Oyster Point Pharma.

Institutional and Insider Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Genocea Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Profitability

This table compares Genocea Biosciences and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
Oyster Point PharmaN/A-39.61%-37.68%

Summary

Genocea Biosciences beats Oyster Point Pharma on 6 of the 10 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Genocea Biosciences and Aptose Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.35

Aptose Biosciences is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Aptose Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
Aptose Biosciences00803.00

Genocea Biosciences currently has a consensus price target of $7.25, indicating a potential upside of 231.05%. Aptose Biosciences has a consensus price target of $11.6250, indicating a potential upside of 139.69%. Given Genocea Biosciences' higher probable upside, equities analysts plainly believe Genocea Biosciences is more favorable than Aptose Biosciences.

Institutional and Insider Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Genocea Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Profitability

This table compares Genocea Biosciences and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
Aptose BiosciencesN/A-49.53%-46.65%

Summary

Aptose Biosciences beats Genocea Biosciences on 6 of the 10 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Genocea Biosciences and Gritstone bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
Gritstone bio$4.36 million97.72$-94,430,000.00($2.81)-3.08

Genocea Biosciences has higher earnings, but lower revenue than Gritstone bio. Gritstone bio is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Gritstone bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
Gritstone bio10202.33

Genocea Biosciences currently has a consensus price target of $7.25, indicating a potential upside of 231.05%. Gritstone bio has a consensus price target of $22.3333, indicating a potential upside of 157.59%. Given Genocea Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Genocea Biosciences is more favorable than Gritstone bio.

Institutional and Insider Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. Comparatively, 59.0% of Gritstone bio shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Comparatively, 38.0% of Gritstone bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Genocea Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Genocea Biosciences and Gritstone bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
Gritstone bio-2,962.52%-101.31%-68.78%

Summary

Genocea Biosciences beats Gritstone bio on 9 of the 13 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Genocea Biosciences and Jounce Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
Jounce Therapeutics$147.87 million2.60$56.82 million$1.664.52

Jounce Therapeutics has higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Jounce Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
Jounce Therapeutics11402.50

Genocea Biosciences currently has a consensus price target of $7.25, indicating a potential upside of 231.05%. Jounce Therapeutics has a consensus price target of $15.50, indicating a potential upside of 104.76%. Given Genocea Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Genocea Biosciences is more favorable than Jounce Therapeutics.

Institutional and Insider Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. Comparatively, 60.5% of Jounce Therapeutics shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Comparatively, 44.0% of Jounce Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Genocea Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares Genocea Biosciences and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
Jounce TherapeuticsN/A-72.91%-59.68%

Summary

Jounce Therapeutics beats Genocea Biosciences on 7 of the 11 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and Codiak BioSciences (NASDAQ:CDAK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Genocea Biosciences and Codiak BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
Codiak BioSciencesN/AN/AN/A

Valuation and Earnings

This table compares Genocea Biosciences and Codiak BioSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
Codiak BioSciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Codiak BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
Codiak BioSciences00303.00

Genocea Biosciences currently has a consensus price target of $7.25, indicating a potential upside of 231.05%. Codiak BioSciences has a consensus price target of $30.00, indicating a potential upside of 67.88%. Given Genocea Biosciences' higher probable upside, equities analysts plainly believe Genocea Biosciences is more favorable than Codiak BioSciences.

Summary

Genocea Biosciences beats Codiak BioSciences on 4 of the 6 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

53.8% of Genocea Biosciences shares are held by institutional investors. Comparatively, 86.7% of AVROBIO shares are held by institutional investors. 2.1% of Genocea Biosciences shares are held by company insiders. Comparatively, 4.8% of AVROBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Genocea Biosciences and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
AVROBION/A-51.33%-47.65%

Valuation & Earnings

This table compares Genocea Biosciences and AVROBIO's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.05
AVROBION/AN/A$-72,960,000.00($2.66)-3.64

AVROBIO is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Genocea Biosciences and AVROBIO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00403.00
AVROBIO03602.67

Genocea Biosciences currently has a consensus target price of $7.25, indicating a potential upside of 231.05%. AVROBIO has a consensus target price of $24.2222, indicating a potential upside of 151.79%. Given Genocea Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Genocea Biosciences is more favorable than AVROBIO.

Risk & Volatility

Genocea Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Summary

Genocea Biosciences beats AVROBIO on 6 of the 11 factors compared between the two stocks.


Genocea Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Oyster Point Pharma logo
OYST
Oyster Point Pharma
0.9$16.31+0.4%$422.14 millionN/A-4.70
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.86+4.9%$410.81 millionN/A-7.59
Gritstone bio logo
GRTS
Gritstone bio
1.6$8.66+5.9%$400.96 million$4.36 million-3.03Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.50+3.6%$370.23 million$147.87 million-2.49
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.86+6.7%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.69+9.3%$367.12 millionN/A-2.94Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.27+1.8%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.66+1.1%$354.53 million$250,000.00-2.88Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03+3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.06+5.8%$336.80 million$8.15 million-1.65Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.73+4.8%$319.64 million$15.36 million-11.71
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.58+1.0%$318.82 million$250,000.00-3.06Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.17+1.9%$316.69 million$2.91 million-2.15Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$11.83+4.3%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44+7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95+3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.13+1.2%$272.63 millionN/A-3.35Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.47+7.3%$218.87 millionN/A-6.91
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.49+4.4%$198.51 million$4.13 million-3.30Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.78+9.0%$196.47 million$29.35 million-2.07Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11+1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.48+4.2%$161.85 million$104.39 million-2.73Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.46+4.0%$161.22 millionN/A-7.88Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.85+4.7%$156.90 million$2.45 million-1.81Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.60+4.5%$152.59 millionN/A-4.62Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$0.99+25.1%$150.00 million$5.65 million-0.59Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.82+8.1%$142.47 millionN/A-3.01Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51+7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.25+9.4%$138.73 millionN/A-10.57Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.44+4.2%$133.43 millionN/A0.00Earnings Announcement
Gap Up
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.02+2.2%$129.76 million$2.33 million0.00News Coverage
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.66+2.7%$129.51 millionN/A-2.39Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.41+2.3%$125.61 millionN/A-1.59Analyst Revision
News Coverage
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.31+2.6%$121.45 million$32.12 million-71.62
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.41+5.6%$116.95 millionN/A-3.25
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.80+6.8%$112.36 million$20,000.000.00Upcoming Earnings
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.15+2.3%$111.36 millionN/A0.00Insider Buying
Dyadic International logo
DYAI
Dyadic International
1.3$3.82+0.5%$105.81 million$1.68 million-11.24Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.02+0.0%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.08+4.4%$97.47 millionN/A0.00Analyst Upgrade
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.75+6.7%$96.07 million$23.05 million-1.67Analyst Downgrade
Analyst Revision
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.01+4.0%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.04+3.8%$90.07 million$3 million-1.94
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60+14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.11+2.7%$65.68 millionN/A-0.88Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.63+0.3%$57.96 million$420,000.00-1.36Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.82+3.9%$56.89 million$7.92 million-0.34Earnings Announcement
News Coverage
BioCardia logo
BCDA
BioCardia
1.2$3.50+5.1%$55.75 million$710,000.00-1.80Earnings Announcement
News Coverage
Gap Up
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.68+2.2%$54.10 million$10,000.000.00
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.01+0.0%$50.53 million$1.45 million-0.35
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.